The Manufacturers Life Insurance Company Acquires New Stake in VBI Vaccines, Inc. – (VBIV)

The Manufacturers Life Insurance Company acquired a new stake in shares of VBI Vaccines, Inc. – (NASDAQ:VBIV) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,509 shares of the biopharmaceutical company’s stock, valued at approximately $126,000.

Other hedge funds also recently modified their holdings of the company. California State Teachers Retirement System purchased a new stake in VBI Vaccines during the second quarter valued at approximately $167,000. Schwab Charles Investment Management Inc. raised its holdings in shares of VBI Vaccines by 36.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 58,200 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 15,400 shares during the period. State Street Corp purchased a new stake in shares of VBI Vaccines in the second quarter worth approximately $831,000. Northern Trust Corp purchased a new stake in shares of VBI Vaccines in the second quarter worth approximately $883,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of VBI Vaccines in the third quarter worth approximately $1,329,000. Institutional investors and hedge funds own 48.64% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of VBI Vaccines stock opened at $3.67 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.26 and a current ratio of 5.32. VBI Vaccines, Inc. – has a fifty-two week low of $3.04 and a fifty-two week high of $5.72.

VBIV has been the topic of several recent analyst reports. Zacks Investment Research upgraded VBI Vaccines from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a report on Saturday, December 23rd. BidaskClub downgraded VBI Vaccines from a “hold” rating to a “sell” rating in a report on Saturday, January 20th. Finally, Noble Financial reiterated a “buy” rating on shares of VBI Vaccines in a report on Friday. Three investment analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $8.75.

TRADEMARK VIOLATION WARNING: This article was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3299313/the-manufacturers-life-insurance-company-acquires-new-stake-in-vbi-vaccines-inc-vbiv.html.

VBI Vaccines Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Institutional Ownership by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Ironwood Pharmaceuticals  Downgraded by Zacks Investment Research
Ironwood Pharmaceuticals Downgraded by Zacks Investment Research
Pentair  Stock Rating Lowered by Zacks Investment Research
Pentair Stock Rating Lowered by Zacks Investment Research
Contrasting Foreign Trade Bank of Latin America  & Its Peers
Contrasting Foreign Trade Bank of Latin America & Its Peers
Contrasting National Presto Industries  and Vista Outdoor
Contrasting National Presto Industries and Vista Outdoor
Financial Survey: Lincoln Electric  versus Spx Flow
Financial Survey: Lincoln Electric versus Spx Flow
J.Jill  Downgraded by ValuEngine
J.Jill Downgraded by ValuEngine


© 2006-2018 Ticker Report. Google+.